1998
DOI: 10.1111/j.1600-0714.1998.tb02100.x
|View full text |Cite
|
Sign up to set email alerts
|

Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma

Abstract: Hamakawa H, Bao Y, Takarada M, Tanioka H: Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma. J Oral Pathol Med 1998; 27: 87–94. © Munksgaard, 1998. The effects of an induction chemotherapy with THP‐adriamycin, cisplatin, and peplomycin (TPP) were studied in 32 patients with operable oral cancer. The histological evaluation according to the Shimozato‐Oboshi classification was Grade (G) IV in ten cases (31.3%), GUI in one case, and Glib in four cases. Induction of ap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2000
2000
2017
2017

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…Tumor suppressor genes-including FHIT, RB1, TP53, and CDKN2A (p16 INK4A )-have been shown to play key roles in HNSCC tumorigenesis (Virgilio et al, 1996;Koontongkaew et al, 2000;Nakahara et al, 2000). Specifically, loss of TP53 function has been shown to correlate with poor response to chemotherapeutic agents such as platinum drugs and fluorouracil, as well as with resistance to radiotherapy (O'Connor et al, 1993;Hamakawa et al, 1998;Temam et al, 2000). In addition, loss of 3p14 and/or 9p21 is considered to be an early event in HNSCC, and, along with TP53 alterations, has been a useful marker for monitoring increased recurrence risk (Brennan et al, 1995;Califano et al, 1996;Gollin, 2001;Rosin et al, 2002).…”
Section: (Ii) Factors Promoting Cin: Loss Of Cell-cycle Control (A) Smentioning
confidence: 99%
“…Tumor suppressor genes-including FHIT, RB1, TP53, and CDKN2A (p16 INK4A )-have been shown to play key roles in HNSCC tumorigenesis (Virgilio et al, 1996;Koontongkaew et al, 2000;Nakahara et al, 2000). Specifically, loss of TP53 function has been shown to correlate with poor response to chemotherapeutic agents such as platinum drugs and fluorouracil, as well as with resistance to radiotherapy (O'Connor et al, 1993;Hamakawa et al, 1998;Temam et al, 2000). In addition, loss of 3p14 and/or 9p21 is considered to be an early event in HNSCC, and, along with TP53 alterations, has been a useful marker for monitoring increased recurrence risk (Brennan et al, 1995;Califano et al, 1996;Gollin, 2001;Rosin et al, 2002).…”
Section: (Ii) Factors Promoting Cin: Loss Of Cell-cycle Control (A) Smentioning
confidence: 99%